FINCAR

This brand name is authorized in Hong Kong, Croatia, South Africa

Active ingredients

The drug FINCAR contains one active pharmaceutical ingredient (API):

1 Finasteride UNII 57GNO57U7G - FINASTERIDE

Finasteride is a competitive inhibitor of human 5α-reductase, an intracellular enzyme which metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor. Read about Finasteride

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
FINCAR Tablet	Web Search	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G04CB01	Finasteride	G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CB Testosterone-5-alpha reductase inhibitors
Discover more medicines within G04CB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 51904
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-126922991
Country: ZA	Health Products Regulatory Authority	Identifier(s): 41/21.12/0422